Citation sources

Updated weekly. Details via Crossref
Crossref Scopus Google Scholar
16 16 Search
2025
Potential protective regulatory effects on radiation−induced esophageal injury in TUT4−/− mice
Frontiers in Oncology
2025
Incidental use of angiotensin system inhibitors during neoadjuvant therapy for esophageal adenocarcinoma: An analysis of survival
The Journal of Thoracic and Cardiovascular Surgery
2025
The Association between use of Renin-Angiotensin-Aldosterone System Inhibitors and the Risk and Mortality of Pancreatic Cancer: A Systematic Review and Meta-Analysis
Current Reviews in Clinical and Experimental Pharmacology
2025
Application of immunotherapy in advanced non-small cell lung cancer with hypertension: a multicenter retrospective analysis
Frontiers in Oncology
2025
Antihypertensive drugs and survival outcomes in oropharyngeal squamous cell carcinoma patients
JNCI: Journal of the National Cancer Institute
2024
An angiotensin system inhibitor (losartan) potentiates antitumor efficacy of cisplatin in a murine model of non–small cell lung cancer
JTCVS Open
2024
Multitarget, multiagent PLGA nanoparticles for simultaneous tumor eradication and TME remodeling in a melanoma mouse model
Drug Delivery and Translational Research
2024
Advanced progress of the relationship between renin–angiotensin–aldosterone system inhibitors and cancers
Journal of Hypertension
2023
Advances in Biochemistry in Health and Disease
2023
Advances in Biochemistry in Health and Disease
2023
Induced Vascular Normalization—Can One Force Tumors to Surrender to a Better Microenvironment?
Pharmaceutics
2022
Cancer Metastasis and Treatment Resistance: Mechanistic Insights and Therapeutic Targeting of Cancer Stem Cells and the Tumor Microenvironment
Biomedicines
2021
Risk of lung cancer and renin–angiotensin blockade: a concise review
Journal of Cancer Research and Clinical Oncology
2021
The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer
Life Sciences
2021
Evaluation of TReatment With Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer: ERACER—An Observational Cohort Study
Journal of Cardiovascular Pharmacology and Therapeutics
Additional cited-by details will be shown when available from Crossref